Ironwood keeps credit facility maturity at 2028

Ironwood Pharmaceuticals, Inc. reported that it has met the liquidity conditions tied to the “Maturity Date” definition in its existing Credit Agreement with Wells Fargo Bank, National Association, as administrative agent.

Accepted by SEC EDGAR 03/11/2026 - 07:05 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Ironwood Pharmaceuticals, Inc. reported that it has met the liquidity conditions tied to the “Maturity Date” definition in its existing Credit Agreement with Wells Fargo Bank, National Association, as administrative agent. As a result, the revolving credit facility’s maturity date remains December 31, 2028, under the current terms of the Credit Agreement.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Ironwood Pharmaceuticals (IRWD) announce in this Form 8-K?

Ironwood Pharmaceuticals announced it has satisfied liquidity conditions under its Credit Agreement. Because of this, the revolving credit facility’s maturity date continues to be December 31, 2028, under the existing agreement terms with Wells Fargo Bank, National Association.

How does this 8-K affect Ironwood Pharmaceuticals’ credit facility maturity date?

The 8-K states that the maturity date for Ironwood’s revolving credit facility remains December 31, 2028. This follows confirmation that the company met the liquidity conditions specified in the “Maturity Date” definition in its amended Credit Agreement with its lending group.

What liquidity-related condition did Ironwood Pharmaceuticals (IRWD) satisfy?

Ironwood satisfied the liquidity conditions referenced in the definition of “Maturity Date” in its Credit Agreement. Meeting these conditions ensures that the revolving credit facility continues to mature on December 31, 2028, instead of triggering an earlier maturity under the contract.

Who is the administrative agent under Ironwood Pharmaceuticals’ Credit Agreement?

Wells Fargo Bank, National Association serves as the administrative agent under Ironwood’s Credit Agreement. The company notified Wells Fargo, as agent, that it had met the required liquidity conditions, confirming that the revolving credit facility’s maturity date remains December 31, 2028.

What type of financing is covered by Ironwood Pharmaceuticals’ Credit Agreement?

The agreement covers a revolving credit facility for Ironwood Pharmaceuticals. After the company satisfied specified liquidity conditions in the Credit Agreement, the maturity date for this revolving credit facility continues to be December 31, 2028, subject to all other terms and conditions.

Who signed the Ironwood Pharmaceuticals (IRWD) 8-K related to the Credit Agreement?

The 8-K was signed on behalf of Ironwood Pharmaceuticals by Gregory Martini. He is identified as the company’s Senior Vice President and Chief Financial Officer, acting as the authorized officer to sign the report concerning the Credit Agreement’s maturity date confirmation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false 0001446847 0001446847 2026-03-10 2026-03-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to 

Section 13 or 15(d) of the 

Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

March 10, 2026

IRONWOOD PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-34620		04-3404176
(State or other jurisdiction				(I.R.S. Employer
of incorporation)		(Commission File Number)		Identification Number)

100 Summer Street, Suite 2300
Boston, Massachusetts				02110
(Address of principal
executive offices)				(Zip code)

(617) 621-7722

(Registrant’s telephone number,

including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A common stock, $0.001 par value	IRWD	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01 Other Events.

On March 10, 2026, Ironwood Pharmaceuticals, Inc. (the “Company”) notified Wells Fargo Bank, National Association, as administrative agent (in such capacity, the “Agent”), under the Credit Agreement, dated May 21, 2023, as amended by Amendment No. 1 to Credit Agreement, dated September 27, 2024 (the “Amended Credit Agreement,” and collectively, the “Credit Agreement”), by and among the Company, as borrower, the Agent and the other agents, lenders and letter of credit issuers parties thereto, that the Company satisfied the liquidity conditions set forth in the definition of “Maturity Date” in the Credit Agreement. Accordingly, the maturity date for the revolving credit facility provided under the Credit Agreement remains December 31, 2028, subject to the other terms and conditions of the Credit Agreement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Ironwood Pharmaceuticals, Inc.
Dated: March 11, 2026	By:	/s/ Gregory Martini
		Name: Gregory Martini
		Title: Senior Vice President, Chief Financial Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.0 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 33.4 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 21.8 KB